Upper-normal blood pressures in otherwise healthy middle-aged men are long-term predictors of incident atrial fibrillation in older age, according to a study that appeared online January 17 in Hypertension.
Upper-normal blood pressures (BP) in otherwise healthy middle-aged men are long-term predictors of incident atrial fibrillation (AF) in older age, according to a study that appeared online January 17 in Hypertension. The study was conducted by a Swedish group led by Irene Grundvold, Department of Cardiology, Oslo University Hospital, Norway.
Researchers recruited 2,014 healthy middle-aged men from 1972 to 1975. They underwent a comprehensive clinical examination, including BP measurements. During up to 35 years of follow-up, 270 men were found to have developed AF. The majority of these developed the condition late in life, on average 20 years from baseline.
Men with baseline systolic BP ≥140 mm Hg and upper-normal BP 128 to 138 mm Hg had 1.60-fold (95% CI, 1.15–2.21) and 1.50-fold (1.10–2.03) risk of AF, respectively, compared with men with BP <128 mm Hg. Baseline diastolic BP ≥80 mm Hg increased the risk of incident AF 1.79-fold (95% CI, 1.28–2.59) compared with diastolic BP <80 mm Hg.
When adjusting for the occurrence of diabetes mellitus or cardiovascular diseases before an AF event, the results still maintained significance. Additional analyses, on average 7 years after baseline, including men still healthy, showed that sustained upper-normal systolic BP remained a significant predictor of subsequent AF.
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
Trelegy and Breo Offer Incremental Improvement Over Generics
March 3rd 2025The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat patients with chronic obstructive pulmonary disease that are part of CMS's drug price negotiation program.
Read More